12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Attenade d-methylphenidate: Phase III

CELG presented previously reported data from two trials involving more than 200 children in which Attenade gave a significant improvement on a behavioral scale compared to placebo (p=0.0003),...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >